Table 1.
Prevalence of anti-pentraxin antibodies in different autoimmune diseases.
| HS | SLE | PAPS | SSc | SS | RA | AAV | Reference |
|---|---|---|---|---|---|---|---|
| Anti-CRP Abs, n (%) | |||||||
| 1/40 (2.5%) | 39/50 (78%) | – | 2/20 (10%) | – | – | – | (59) |
| 5/100 (5%) | 13/27 (48%) | – | – | 2/16 (12.5%) | 0/15 (0%) | – | (62) |
| 4/80 (5%) | 77/137 (51%) | 68/127 (54%) | – | – | – | – | (63) |
| – | 43/190 (22.6%) | – | – | – | 23/103 (22.3%) | – | (64) |
| 2/45 (4.4%) | 12/150 (8%) | – | – | – | – | – | (65) |
| 0/60 (0%) | 20/49 (40.8%)* 56/96 (59.3%)** |
– | – | – | – | – | (66) |
| 1/34 (2.9%) | 18/81 (22.2%) | – | – | – | – | – | (67) |
| 0/60 (0%) | – | – | – | 2/7 (28.6%) | – | 1/20 (5%) | (68) |
| – | 26/100 (26%) | – | – | – | – | – | (69) |
| 21.01 ± 14.32 | 35.6 ± 35.1 | – | – | – | – | – | (70) |
| 5/92 (5.4%) | – | – | – | – | – | 11/120 (9.2%) | (71) |
| 10/36 (27.8%) | 18/34 (52.9%) | – | – | – | – | – | (72) |
| Anti-SAP Abs, n (%) | |||||||
| 3/124 (2.4%) | 145/328 (44%) | – | – | – | – | – | (73) |
| 1/45 (2.2%) | 20/100 (20%) | – | – | – | – | – | (65) |
| 3/93 (3.2%) | – | – | – | – | – | 21/120 (17.5%) | (71) |
| Anti-PTX3 Abs, n (%) | |||||||
| 4/93 (4.3%) | 18/36 (50%) | – | – | – | 1/40 (2.5%) | – | (55) |
| 8/130 (6.2%) | 60/130 (46.2%) | – | 1/26 (3.8%) | 2/26 (7.7%) | 2/27 (7.1%) | – | (74) |
| 12/227 (5.3%) | – | – | – | – | – | 56/150 (37.3%) | (71) |
| 2/100 (2%) | 38/196 (19.4%)** 61/150 (40.7%)* |
– | – | – | – | – | (75) |
HS, healthy subjects; SLE, systemic lupus erythematosus; PAPS, primary antiphospholipid syndrome; SSc, systemic sclerosis; SS, Sjögren syndrome; RA, rheumatoid arthritis; AAV, ANCA-associated vasculitis.
∗SLE patients without lupus nephritis.
∗∗SLE patients with lupus nephritis.